Targeting eryptosis—alongside optimizing EPO and iron therapy—may represent a novel strategy to improve anemia management in NDD-CKD, though further longitudinal studies are needed to confirm causality and identify actionable molecular targets. The gene discussed is EPO; the disease is anemia (phenotype).